Ology Bioservices Awarded US Army Contract to Manage Production of COVID-19 Vaccines and Therapeutics
The contract is valued at $106.3 million and is supported by Operation Warp Speed.
Ology Bioservices, a biologics contract development and manufacturing organization based in Frederick, MD, announced on Aug. 26, 2020 that it has been contracted by the US Army Contracting Command at Aberdeen Proving Ground in Maryland to manage the production capacity of approximately 186,840,000 doses of COVID-19 vaccines and therapeutics.
The contract is valued at $106.3 million and is supported by Operation Warp Speed, a company press release said.
“Along with producing vaccines and monoclonal antibodies to eventually combat the spread of COVID-19, the team at Ology Bioservices is very proud to support the fill and finishing network as needed by Operation Warp Speed,” said Peter H. Khoury, PhD, president and CEO of Ology Bioservices, in the press release.
Source: Ology
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
